Given pre-clinical cancer studies that found co-blockade of the PD-1/Tim-3 pathway endowed successful control over tumor growth, whether the joint effect of Tim-3 and PD-1 also make optimal protection to the fetus is attractive. Here, HAVCR2 is linked to cancer.